Medicaid officials said drugmaker Mylan NV, which has been the focus of controversy over its EpiPen pricing policy, bilked taxpayers of a substantial sum by overcharging Medicaid for the life-saving devices.Medicaid spent $960 million on EpiPens from 2011 to 2015, the Centers for Medicare and Medicaid Services reported. When Medicare Part D is added in, the total goes to nearly $1.3 billion. The total includes 13 percent in rebates, but CMS said the program should have received a 23.1 percent discount plus the difference between the rate of inflation and any price increase since EpiPen is a brand name drug without any generic equivalent.Mylan acquired the drug in 2007 and has been raising the price steadily since. The price has gone from $100 for a two-pack in 2007 to $608 this year.“Today’s letter is more evidence that while Mylan irresponsibly raised the price of EpiPen, they were also bilking taxpayers out of millions of dollars,” Sen. …
Go to Source
EpiPen Price Figures: Mylan Accused Of Bilking Medicaid Program By Misclassifying Drug, Holding Back Rebates – International Business Times